BioNxt Solutions Accelerates U.S. Patent and Secures Broad IP for Neurological Autoimmune Disorders

BioNxt Solutions Inc. has taken significant steps in advancing its proprietary drug delivery platform focusing on neurological autoimmune disorders. The Vancouver-based bioscience company has initiated a fast-tracked examination process for its U.S. patent application, BNT23001, under the USPTO's Track One Program. This patent covers a novel sublingual thin-film formulation of cladribine for multiple sclerosis (MS).

Simultaneously, BioNxt received core claim acceptance for a wide-reaching international patent protecting its drug delivery technology across various diseases. This achievement grants extended exclusivity into the 2040s, crucial for the company's strategic expansion and partnership opportunities. The patented platform aims to improve patient compliance with superior bioavailability of its sublingual formulations compared to traditional tablets.

The company plans to conduct preclinical studies shortly to affirm its product's efficacy and efficiency, targeting the MS and generalized myasthenia gravis markets, estimated to be worth $42-46 billion by 2032.